US recommends ‘pause’ on Johnson & Johnson COVID-19 vaccine After Blood clot cases

After the six adverse cases of blood clotting, the US recommends pausing Johnson and Johnson covid-19 vaccine. This was the joint decision of the US Center for Disease and Prevention [CDC] and the Food and Drug Administration [FDA] to halt Johnson and Johnson Covid-19 vaccine usage. Here’s what Dr. Anne Schuchat, Principal Deputy Director of the CDC, told the media ‘Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution.’

The decision was made public yesterday [13th April 2021] around 4 p.m. through a tweet by the FDA. A total of six cases are considered under the adverse case in which the people suffer from reduced platelets and blood clotting. According to the FDA

, the treatment of this blood clotting will be different from the others. One more strange thing to notice is that all six people are women between the age gap of 18 to 48.

However, the Johnson and Johnson company is denying the whole situation. Their officials have said ‘no clear causal relationship’ between the vaccine and the blood clotting. The truth will be in front of the entire nation after the investigation is completed; we have to wait till then.

CDC announced an Advisory committee on immunization practices [ACIP] on Wednesday to review the whole case. The Johnson and Johnson company is also taking precautions and has stopped its stock exchange with various European countries and negotiated new terms. Here’s what company officials said to the media: “We have been reviewing these cases with European health authorities. We have decided to delay the rollout of our vaccine in Europe proactively.”

 

Also read: Zack Snyder’s Army of the Dead Netflix Trailer And Release Date